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Reply from the Authors
We thank Odamaki et al for their comments and for
sharing their interesting cross-sectional data on Japanese
subjects. These data add to the growing body of evidence
supporting a causative relationship between low fetuin-A
levels, inflammation, and the vascular calcification pro-
cess in patients with chronic kidney disease. As of today,
studies in Caucasian [1, 2], African American [2], and
Asian [3] patients with end-stage renal disease (ESRD)
all show associations between low serum levels of fetuin-
A and vascular calcification, measured by either carotid
ultrasonography or computer tomography. Furthermore,
emerging evidence suggests a causative relationship be-
tween decreased levels of serum fetuin-A, increased ion-
ized calcium in the blood, and vascular calcification [4, 5].
However, our understanding of this process is far from
complete, as demonstrated by a recent study in predia-
lytic patients with diabetic nephropathy, which found a
direct positive relationship between serum fetuin-A lev-
els and coronary artery calcification [6]. It will thus be
of interest to further study underlying factors, including
gene-environment interactions such as polymorphisms of
the AHSG gene [1], and their associations with vascular
calcification in different ethnic populations.
In their study, Odamaki et al mention that serum
fetuin-A levels correlate with serum adiponectin lev-
els, but do not mention if this relationship is present
after correction for inflammation. Several studies have
demonstrated that serum fetuin-A acts as a negative
acute-phase reactant, thus decreasing during inflamma-
tion [1–3], while we have previously shown that serum
inflammation is also associated with lower levels of
serum adiponectin in ESRD patients [7]. A putative link
between these two exists because adipose tissue is an im-
portant source of both adiponectin [7] and proinflamma-
tory cytokines such as interleukin (IL)-6 [8] in this patient
group.
While the available data derived from cross-sectional
studies are certainly interesting, the next step will be to
find interventions modulating fetuin-A and other cal-
cification inhibitors, and to test these in well-designed,
prospective studies in an attempt to impact the all too
high cardiovascular morbidity and mortality currently
seen in our patients. The first such studies, using unspe-
cific and targeted anti-inflammatory treatment strategies,
are currently underway, and we are eagerly awaiting the
results.
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